Stifel Financial Corp Zymeworks Inc. Transaction History

Stifel Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$33.67 - $40.0 $517,945 - $615,320	-15,383 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$24.28 - $49.8 $558,877 - $1.15 Million	-23,018 Reduced 59.94%	15,383 $547,000
Q4 2019 Feb 13, 2020	SELL	$24.84 - $45.46 $185,306 - $339,131	-7,460 Reduced 16.27%	38,401 $1.75 Million
Q3 2019 Nov 13, 2019	BUY	$22.78 - $29.08 $398,604 - $508,841	17,498 Added 61.69%	45,861 $1.14 Million
Q2 2019 Aug 14, 2019	BUY	$15.0 - $22.49 $425,445 - $637,883	28,363 New	28,363 $622,000
Q3 2018 Nov 13, 2018	SELL	$12.21 - $16.61 $216,568 - $294,611	-17,737 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$11.13 - $21.86 $197,412 - $387,730	17,737 New	17,737 $262,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $949M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.